Stage
Seed | AliveAbout MedElute
MedElute is a start-up based in Michigan that has been granted a paid up license from Angiotech Pharmaceutical, Inc. as part of the merger transaction between Angiotech and Afmedica, Inc. The license is for rights to a pending patent (not yet issued) in which claims are made for methods and materials to treat post surgical adhesions with a highly anti-platelet approach.
MedElute Headquarter Location
Kalamazoo, Michigan, 49001,
United States
You May Also Like
Quark Pharmaceuticals is a development-stage pharmaceutical company discovering and developing RNA interference (RNAi)-based therapeutics.
Oculus Innovative Sciences develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform features a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized in the United States, Europe, India, China and Mexico for the treatment of infected wounds. The solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. The company's headquarters are in Petaluma, California, with operations in Europe and Latin America.
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
ThyroChek is the only available rapid test for elevated TSH approved by the FDA. It is a rapid, qualitative test for elevated TSH, thyroid stimulating hormone, a clinical indicator of hypothyroidism. Screening Devices Canada is producing products for the thyroid health market in the United States which is a market valued at $1.2B annually.
Novalar Pharmaceuticals develops a drug agent that is designed to reverse the effects of local anesthesia applied in dental procedures, thereby allowing patients to return to their daily activities without the speech impediments, lip biting, and difficulty in eating that can be caused by unintended soft-tissue anesthesia.
Banyan Biomarkers has created a Point of Care (POC) Blood Test to diagnose traumatic brain injury (TBI). Banyan Biomarkers' research has identified unique biomarkers present in the patient's blood following injury to the brain. The detection and quantification of these biomarkers may provide early indications of brain trauma essential for earlier intervention and management.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.